TSX runs higher on rate cut expectations
LONDON - N4 Pharma PLC, a pharmaceutical company, has notified the market of a significant change in its major holdings. On April 23, 2025, Mathenz Marc Kay crossed a notable threshold in voting rights attached to the company’s shares.
According to the standard form for notification of major holdings, Mathenz Marc Kay now holds 8.89% of the voting rights in N4 Pharma PLC, which equates to 74,000,000 shares. This change represents a slight decrease from the previous notification, where the holding was reported at 9.12%.
The notification, completed in Singapore on May 23, 2025, also revealed that UOB Kay Hian Singapore Pte Ltd acts as the proxy holder for these voting rights, maintaining the same percentage of 8.89%.
The adjustment in shareholding has been disclosed in accordance with the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority. It is a standard regulatory requirement for investors to inform a public company when their shareholding crosses certain percentage thresholds.
The London Stock Exchange (LON:LSEG)’s news service, RNS, reported this information, which is essential for investors and the market to track ownership and potential influence within publicly traded companies.
N4 Pharma PLC has not commented beyond the regulatory filing, and the reasons behind Mathenz Marc Kay’s adjustment in their stake have not been disclosed. The company continues to operate in the pharmaceutical sector, with this change in major holdings now a part of its investment landscape.
This notification is based on a press release statement and is intended to keep shareholders and the market informed of significant changes in share ownership.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.